Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | Phase2 | Australia Brazil Canada China France Germany Hungary Italy Japan Netherlands Poland South Korea Spain Thailand United States View all |
NCT07354074 |
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population |
Hidradenitis Suppurativa | Italy | NCT07543419 | |
REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria |
Paroxysmal Nocturnal Hemoglobinuria (PNH) | Italy | NCT07229235 | |
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) |
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) | Phase3 | Argentina Australia Austria Belgium Brazil Canada China Czechia France Germany India Italy Japan Malaysia Netherlands Poland South Korea Spain Switzerland Taiwan Turkey (Türkiye) United States View all |
NCT07357727 |
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction |
Heart Failure With Reduced Ejection Fraction | Phase1 | Canada United States |
NCT07465653 |
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy |
Secondary Malignancies of T-cell Origin | Japan | NCT07378969 | |
Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China |
HR+/HER2- Advanced or Metastatic Breast Cancer | China | NCT07476170 | |
Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings |
Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice | Germany | NCT07508007 | |
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China |
Chronic Myeloid Leukemia in Chronic Phase | China | NCT07375355 | |
A Study to Assess the Effects of Zigakibart on IgA Nephropathy. |
Immunoglobulin A Nephropathy (IgAN) | Phase2 | Brazil China Czechia Germany Italy Japan Poland South Korea Spain Taiwan United States View all |
NCT07146906 |